Status: Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Participants needed: 1,500
Trial details
Biological sex: AllType: ObservationalSponsor: Alnylam PharmaceuticalsUpdated: May 29, 2026Locations: 40
Eligibility criteria
Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant fo... [+1]
Current enrollment in a clinical trial for any investigational agent